News|Articles|October 22, 2025

Conference Preview: Fall Clinical Dermatology Conference 2025

This conference preview for the 2025 Fall Clinical Dermatology meeting highlights upcoming sessions and interviews.

The 2025 Fall Clinical Dermatology Conference will convene in Las Vegas, Nevada, from October 23–26, 2025, bringing together leaders in medical, aesthetic, and surgical dermatology to present recent data and clinical pearls for everyday practice. As one of the most comprehensive educational meetings in the specialty, Fall Clinical is set to provide varying sessions blending emerging research with practical strategies to improve patient outcomes in dermatology.

Related to this article

October 5th, 2026

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.

October 5th, 2026

Q&A: Dupilumab Improves Quality of Life in Omalizumab-Naive CSU

Thomas Casale, MD, discusses pooled CUPID A and C data showing dupilumab improved quality of life in omalizumab-naive chronic spontaneous urticaria.

October 3rd, 2026

EADV 2026: Telikibart Attains EASI-75 in 70% at Week 16 in Atopic Dermatitis

In a phase 3 study, telikibart achieved EASI-75 in 69.6% of adult patients with atopic dermatitis at Week 16, with rates above 94% by Week 52.

October 3rd, 2026

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

An indirect comparison finds higher placebo-adjusted skin and itch responses with upadacitinib vs nemolizumab in atopic dermatitis.

October 3rd, 2026

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Check out highlights from news published on Day 3 of the EADV Congress 2026, spanning psoriasis, cutaneous lupus, atopic dermatitis, and more.

October 2nd, 2026

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

Werth discusses what the 52-week AMETHYST Part A data add to the case for litifilimab in antimalarial-refractory cutaneous lupus erythematosus.

October 2nd, 2026

7 Dermatology Headlines You Missed in September 2026

From a pediatric alopecia areata approval to head-to-head TYK2 data at EADV, here are 7 dermatology stories from September 2026.

October 2nd, 2026

ICONIC-TOTAL: Icotrokinra Sustains High-Impact Site Clearance at 2 Years

Oral icotrokinra sustained clearance at scalp, genital, hand/foot, and nail sites through Week 112 in ICONIC-TOTAL, with no rise in adverse event rates.